POST Online Media Lite Edition



 

United Therapeutics buys Arena's hypertension drug ralinepag in deal worth $1.2 billion

Staff Writer |
Arena Pharmaceuticals and United Therapeutics Corporation announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).


Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.

In return, Arena will receive up to $1.2 billion, including an upfront payment of $800 million and potential milestone payments totaling up to $400 million based on the achievement of certain regulatory events. Additionally, Arena will receive low double-digit tiered royalties on annual net sales of ralinepag.


What to read next

Bristol-Myers Squibb to pay $1.85 billion in cancer deal with Nektar
Cardinal Health to buy Harvard Drug Group for $1.12 billion
China's Fosun Pharma to acquire 74 percent stake in Gland Pharma for $1.1 billion